Chen, TWW, Giani, C, Ljevar, S, Reinhorn, D, Denu, R, Bhadri, VA, Jaeger, R, Ibrahim, T, D'Ambrosio, L, Bae, S, Han, I, Garcia, AS, Abreu, MH, Ribeiro, MFSA, Mariuk-Jarema, A, Yang, V, Sbaraglia, M, Antonescu, C, Baldi, GG, Stacchiotti, S. International multicenter retrospective study of spindle cell/ sclerosing rhabdomyosarcoma (S-RMS): A PUSH platform study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3306. PMID:. IF:65.400(Q1/1D).

Cerna, JGY, Mirallas, O, Garces, VN, Puerto, DAG, Velilla, G, Pastor, PG, Puga, TG, Salgado, MAV, Martínez, A, Gonzalez, AH, Sorolla, MA, Di Muzio, A, González, M, Martinez-Garcia, MJ, Villacampa, G, Balana, C, Galceran, JC, Dienstmann, R, Sanchez, JMS, Vieito, M. Molecular landscape of IDH1/2-mutant gliomas: A Spanish multicentric cohort. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1270. PMID:. IF:65.400(Q1/1D).

Muñiz, NH, Strauss, S, Redondo, A, Palmerini, E, Gaffaro, GJM, Chamberlain, FE, Martinez, V, Ibrahim, T, Trufero, JM, Morales, CMV, Billalabeitia, EG, Lleida, RT, Jiménez, CL, Mukherjee, U, Wan, S, Ramos, R, Garcia, AMG, Moura, DD, Martin-Broto, J. Phase II of sunitinib plus nivolumab in advanced alveolar soft-part sarcoma results from the GEIS, ISG and UCL IMMUNOSARC II study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3296. PMID:. IF:65.400(Q1/1D).

Hwang, T, Kesselheim, A, Tibau, A. Magnitude of clinical benefit of cancer medicines in curative setting and health technology assessment decisions in Europe. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2893. PMID:. IF:65.400(Q1/1D).